Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crefmirlimab - ImaginAb Inc

Next Previous
X
Search
Drug Profile

Crefmirlimab - ImaginAb Inc

Alternative Names: 89-Zr CD8 ImmunoPET minibody - ImaginAb Inc; 89Zr CD8 Immuno-PET agent - ImaginAb; 89Zr-crefmirlimab berdoxam - ImaginAb; 89Zr-Df-crefmirlimab - ImaginAb; 89Zr-Df-IAB22M2C - ImaginAb; [89Zr]-Df-Crefmirlimab; [89Zr]Df-IAB22M2C; CD8 T cell I/O imaging agent; CD8 T Cell imaging agent; CD8-ImmunoPET; IAB 22 M2C; Minibody CD8 T Cell imaging agent; Zirconium 89Zr crefmirlimab berdoxam; Zr-89 IAB22M2C

Latest Information Update: 07 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImaginAb Inc
  • Class Antibody diagnostics; Antineoplastics; Diagnostic agents; Imaging agents; Immunoconjugates; Immunoglobulin fragments; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Malignant melanoma; Renal cell carcinoma
  • Phase II Inclusion body myositis; Merkel cell carcinoma; Non-small cell lung cancer; Solid tumours
  • No development reported Cervical cancer; Gastric cancer; Graft-versus-host disease

Most Recent Events

  • 02 Aug 2024 ImaginAB in collaboration with University Medical Center Groningen plans a phase II trial for Solid tumours (Late-stage disease, Metastatic disease, Second line therapy or greater, Diagnosis) in Netherlands, Spain and United Kingdom (Unspecified)(NCT06534190)
  • 25 Jan 2024 Interim pharmacokinetics data from a phase II in solid tumours presented at the 2024 Genitourinary Cancers Symposium (ASCO-GSC-2024)
  • 02 Jun 2023 Efficacy data from phase II trial for Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top